02526 德適－Ｂ
DIAGENS-B
DIAGENS-B
| Register Close | 2026/03/25 IPO Closing in 5 Days |
| Listing Date | 2026/03/30 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Hangzhou Diagens Biotechnology Co. was established in 2016, it is a medical device company focusing on developing medical imaging products and services. The Group has self-developed a diversified portfolio, which comprises: six medical imaging software products, including its Core Product, AI AutoVision®, which is at the registration stage, one commercialized product, AutoVision®, as well as four pre-clinical stage product candidates; three commercialized medical devices; and four key reagents and consumables.
--
The Group’s Core Product, AI AutoVision®, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The Group has initially established a nationwide distribution network of 75 distributors, successfully covering over 400 healthcare centers and medical institutions in 31 provinces, autonomous regions and municipalities as of September 30, 2025.
--
As of March 10, 2026, the Group has established one production facility located in Hangzhou, Zhejiang Province, namely the Smart Health Valley Production Base, with 18 manufacturing personnel and a total of four production lines, all of which focus on manufacturing medical devices and medical imaging software, with annual designed production capacity of 2,000 units.
--
The Group’s customers are primarily distributors, hospitals, digital infrastructure service providers, medical institutions, research organizations and third-party medical laboratories.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 50 |
GLOBAL OFFERING
| No. of Offer Shares | 8.00M H shares |
| No. of International Offer Shares | 7.20M H shares |
| No. of HK Offer Shares | 0.80M H shares |
| Offer Price | $95.60 - $112.50 |
| Stock Code | 2526 |
| Sponsor(s) | Huatai Financial Holdings (Hong Kong) Limited |
| Underwriter(s) | Huatai Financial Holdings (Hong Kong) Limited, Futu Securities International (Hong Kong) Limited, ABCI Securities Company Limited, BOCI Asia Limited, CCB International Capital Limited, China Galaxy International Securities (Hong Kong) Co., Limited, Huafu International Securities Limited, Yellow River Securities Limited, Yuen Meta (International) Securities Limited, Yunfeng Securities Limited, Zheshang International Financial Holdings Co., Limited |
TIME TABLE
| Application Period | Mar 20 (Fri) - noon, Mar 25 (Wed) |
| Price Determination Date | Mar 26 (Thu) |
| Result Announcement Date | On or before Mar 27 (Fri) |
| Result Announcement Date | On or before Mar 27 (Fri) |
| Result Announcement Date | On or before Mar 30 (Mon) |
| Dealings in Shares commence on | Mar 30, 2026. (Mon) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $95.60 - $112.50 |
| Capitalization (H Shares) | 8.50B - 10.00B |
| NAV / share ($) | $10.57 - $12.03 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 104.1, the net proceeds raised would be HKD 762.90M, of which |
| 49% : Development and commercialization of Core Product AI AutoVision® |
| 10% : Research and development of other medical imaging software product candidates and medical devices |
| 20% : Enhance iMedImage® foundation model and AI technologies as well as to strengthen technology licensing business |
| 8% : Strengthen commercialization capabilities and market penetration in China |
| 5% : Expand presence in global markets |
| 8% : Pursue strategic collaboration and investment opportunities |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).